Systemic therapy for HCC: Doublets, triplets and beyond.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with most patients requiring systemic therapy at diagnosis or during disease progression. Immune checkpoint inhibitor (ICI)-based combinations have transformed the therapeutic landscape and are now the standard first-line treatment, demonstrating improved survival and higher response rates compared with earlier tyrosine kinase inhibitor-based approaches.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, with most patients requiring systemic therapy at diagnosis or during disease progression. Immune checkpoint inhibitor (ICI)-based combinations have transformed the therapeutic landscape and are now the standard first-line treatment, demonstrating improved survival and higher response rates compared with earlier tyrosine kinase inhibitor-based approaches.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Hepatol
Why it surfaced
Matched watchlist topic 'Precision oncology and genomic medicine'. Study design: Review. Score: 8/10 (N:3, R:3, D:1, P:1).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.